Difference between revisions of "Degarelix (Firmagon)"
m |
m |
||
| Line 15: | Line 15: | ||
==History of changes in FDA indication== | ==History of changes in FDA indication== | ||
| − | *2008-12-24: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129207.htm | + | *2008-12-24: [http://www.fda.gov/AboutFDA/CentersOffices/OfficeofMedicalProductsandTobacco/CDER/ucm129207.htm Approved] for treatment of patients with advanced [[prostate cancer]]. ''(Based on CS21)'' |
==History of changes in EMA indication== | ==History of changes in EMA indication== | ||
*2009-02-17: Initial authorization | *2009-02-17: Initial authorization | ||
| + | ==History of changes in Health Canada indication== | ||
| + | *2009-11-16: Initial notice of compliance for testosterone suppression in patients with advanced hormone-dependent [[prostate cancer]] in whom androgen deprivation is warranted. | ||
==Also known as== | ==Also known as== | ||
*'''Code name:''' ASP3550, FE200486 | *'''Code name:''' ASP3550, FE200486 | ||
| Line 34: | Line 36: | ||
[[Category:FDA approved in 2008]] | [[Category:FDA approved in 2008]] | ||
[[Category:EMA approved in 2009]] | [[Category:EMA approved in 2009]] | ||
| + | [[Category:Health Canada approved in 2009]] | ||
Revision as of 00:10, 10 May 2023
General information
Class/mechanism: Gonadotropin-releasing hormone (GnRH) receptor antagonist. Reversibly binds to pituitary GnRH receptors, reducing the release of luteinizing hormone (LH) and follicle stimulation hormone (FSH), resulting in rapid androgen deprivation/decreased testosterone levels. There is no initial testosterone surge/flare with degarelix, in contrast to GnRH agonists.[1][2][3]
Route: SC
Extravasation: n/a
For conciseness and simplicity, HemOnc.org currently will focus on treatment regimens and not list information such as: renal/hepatic dose adjustments, metabolism (including CYP450), excretion, monitoring parameters (although this will be considered for checklists), or manufacturer. Instead, for the most current information, please refer to your preferred pharmacopeias such as Micromedex, Lexicomp, UpToDate (courtesy of Lexicomp), or the prescribing information.[1]
Diseases for which it is used
Patient drug information
- Degarelix (Firmagon) package insert[1]
- Degarelix (Firmagon) patient drug information (Chemocare)[4]
- Degarelix (Firmagon) patient drug information (UpToDate)[5]
History of changes in FDA indication
- 2008-12-24: Approved for treatment of patients with advanced prostate cancer. (Based on CS21)
History of changes in EMA indication
- 2009-02-17: Initial authorization
History of changes in Health Canada indication
- 2009-11-16: Initial notice of compliance for testosterone suppression in patients with advanced hormone-dependent prostate cancer in whom androgen deprivation is warranted.
Also known as
- Code name: ASP3550, FE200486
- Generic name: degarelix acetate
- Brand name: Firmagon